Skip to main content
Fig. 3 | BMC Pharmacology and Toxicology

Fig. 3

From: GR113808, a serotonin receptor 4 antagonist, prevents high-fat-diet-induced obesity, fatty liver formation, and insulin resistance in C57BL/6J mice

Fig. 3

GR113808 prevents HFD-induced fatty liver formation. A histological analysis of the liver (scale bar: 100 μm) (A) and the triglyceride amount in (B) the liver (n = 10) are shown. (C) Representative western blots (left) and densitometric analysis (right) for the indicated antibody using liver lysates (n = 3). (D) Relative mRNA levels of genes related to lipogenesis (SREBP-1c, FAS, SCD-1, Agpat1, PPAR-γ, and Mogat1), fatty acid uptake (CD36, FABP1, and FATP5), and fatty acid oxidation (CPT1a, Acox1, and PPARα) in the livers of mice injected with GR113808 (n = 6). A student’s t-test was performed. Error bars on plots represent standard deviation (SD); *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations Acox1 acyl-CoA oxidase 1, Agpat1 1-acylglycerol-3-phosphate O-acyltransferase 1, CD36 cluster of differentiation 36, CPT1a carnitine palmitoyl transferase 1a, eIF2α eukaryotic translation initiation factor 2α, FABP fatty acid binding protein, FAS fatty acid synthase, FATP fatty acid transport protein, HFD high-fat diet, Mogat1 monoacylglycerol O-acyltransferase 1, PERK protein kinase R-like endoplasmic reticulum kinase, PPAR peroxisome proliferator-activated receptor, SCD standard chow diet, SCD-1 stearoyl-CoA desaturase 1, m-SREBP1 mature form of sterol regulatory element-binding protein 1

Back to article page